# A Study to Learn How the Body Processes Spironolactone and Hydrochlorothiazide Film Coated Tablets Manufactured at Two Sites: Viatris and Neolpharma

> **NCT06205407** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 42 (actual)

## Conditions studied

- Healthy Participants

## Interventions

- **DRUG:** Spironolactone/Hydrochlorothiazide (25 mg/25 mg) film coated tablets from Viatris
- **DRUG:** Spironolactone/Hydrochlorothiazide (25 mg/25 mg) film coated tablets from Neolpharma.

## Key facts

- **NCT ID:** NCT06205407
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-12-26
- **Primary completion:** 2024-03-01
- **Final completion:** 2024-03-01
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2025-03-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06205407

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06205407, "A Study to Learn How the Body Processes Spironolactone and Hydrochlorothiazide Film Coated Tablets Manufactured at Two Sites: Viatris and Neolpharma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06205407. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*